Overexpression of primary microRNA 221/222 in acute myeloid leukemia

BackgroundAcute myeloid leukemia (AML) is a hematopoietic malignancy with a dismal outcome in the majority of cases. A detailed understanding of the genetic alterations and gene expression changes that contribute to its pathogenesis is important to improve prognostication, disease monitoring, and therapy. In this context, leukemia-associated misexpression of microRNAs (miRNAs) has been studied, but no coherent picture has emerged yet, thus warranting further investigations.MethodsThe expression of 636 human miRNAs was compared between samples from 52 patients with AML and 13 healthy individuals by highly specific locked nucleic acid (LNA) based microarray technology. The levels of individual mature miRNAs and of primary miRNAs (pri-miRs) were determined by quantitative reverse transcriptase (qRT) PCR. Transfections and infections of human cell lines were performed using standard procedures.Results64 miRNAs were significantly differentially expressed between AML and controls. Further studies on the clustered miRNAs 221 and 222, already known to act as oncogenes in other tumor types, revealed a deficiency of human myeloid cell lines to process vector derived precursor transcripts. Moreover, endogenous pri-miR-221/222 was overexpressed to a substantially higher extent than its mature products in most primary AML samples, indicating that its transcription was enhanced, but processing was rate limiting, in these cells. Comparison of samples from the times of diagnosis, remission, and relapse of AML demonstrated that pri-miR-221/222 levels faithfully reflected the stage of disease.ConclusionsExpression of some miRNAs is strongly regulated at the posttranscriptional level in AML. Pri-miR-221/222 represents a novel molecular marker and putative oncogene in this disease.

[1]  Shuang Huang,et al.  Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression. , 2011, Genes & cancer.

[2]  Jin-Wu Nam,et al.  Genomics of microRNA. , 2006, Trends in genetics : TIG.

[3]  Giovanni Vanni Frajese,et al.  The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice , 2008, PloS one.

[4]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[5]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[6]  Gerhard G. Thallinger,et al.  ArrayNorm: comprehensive normalization and analysis of microarray data , 2004, Bioinform..

[7]  K. Suzukawa,et al.  Establishment of a novel human myeloid leukaemia cell line (HNT‐34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome , 1997, British journal of haematology.

[8]  Ru Huang,et al.  The function of non-coding RNAs in genomic imprinting , 2009, Development.

[9]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[10]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[11]  Reuven Agami,et al.  Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation , 2007 .

[12]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[13]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[14]  Bob Löwenberg,et al.  MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. , 2008, Blood.

[15]  U. Testa,et al.  MicroRNAs in normal and malignant myelopoiesis. , 2009, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[16]  Joel S Parker,et al.  Extensive post-transcriptional regulation of microRNAs and its implications for cancer. , 2006, Genes & development.

[17]  H. Koeffler,et al.  Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. , 1978, Science.

[18]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[19]  A. Hochberg,et al.  H19 in normal development and neoplasia , 1997, Molecular reproduction and development.

[20]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[21]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[22]  Eric S. Lander,et al.  Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse , 2005, Cell.

[23]  J. T. Syverton,et al.  STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES , 1952, The Journal of experimental medicine.

[24]  M. Dugas,et al.  Identification of acute myeloid leukaemia associated microRNA expression patterns , 2007, British journal of haematology.

[25]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[26]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[27]  W. Filipowicz,et al.  Repression of protein synthesis by miRNAs: how many mechanisms? , 2007, Trends in cell biology.

[28]  S. Collins,et al.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.

[29]  T. Golub,et al.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.

[30]  R. Gregory,et al.  Many roads to maturity: microRNA biogenesis pathways and their regulation , 2009, Nature Cell Biology.

[31]  Jean-Baptiste Cazier,et al.  Distinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia , 2008, PloS one.

[32]  W. Hiddemann,et al.  Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia , 1997 .

[33]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[34]  W. O'Gorman,et al.  The potential functions of primary microRNAs in target recognition and repression , 2010, The EMBO journal.

[35]  M. Mildner,et al.  miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging , 2010, Aging cell.

[36]  B. Löwenberg Acute myeloid leukemia: the challenge of capturing disease variety. , 2008, Hematology. American Society of Hematology. Education Program.

[37]  Z. Trajanoski,et al.  microRNAs in acute myeloid leukemia: Expression patterns, correlations with genetic and clinical parameters, and prognostic significance , 2009, Genes, chromosomes & cancer.

[38]  J. Lehman,et al.  Human cell line that differentiates to all myeloid lineages and expresses neutrophil secondary granule genes. , 2000, Experimental hematology.

[39]  G. Cammarata,et al.  Differential expression of specific microRNA and their targets in acute myeloid leukemia , 2010, American journal of hematology.

[40]  D. Spector,et al.  Long noncoding RNAs: functional surprises from the RNA world. , 2009, Genes & development.

[41]  R. Greil,et al.  Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma , 2010, Proceedings of the National Academy of Sciences.

[42]  Leighton J. Core,et al.  Nascent RNA Sequencing Reveals Widespread Pausing and Divergent Initiation at Human Promoters , 2008, Science.

[43]  C. Croce,et al.  Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing , 2007, Proceedings of the National Academy of Sciences.

[44]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[45]  S. Hammond,et al.  Emerging paradigms of regulated microRNA processing. , 2010, Genes & development.

[46]  K. Nilsson,et al.  Establishment and characterization of a human histiocytic lymphoma cell line (U‐937) , 1976, International journal of cancer.

[47]  B. Cullen,et al.  The imprinted H19 noncoding RNA is a primary microRNA precursor. , 2007, RNA.

[48]  A. Hochberg,et al.  The H19 Non-Coding RNA Is Essential for Human Tumor Growth , 2007, PloS one.

[49]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[50]  J. Rinn,et al.  Large non-coding RNAs: missing links in cancer? , 2010, Human molecular genetics.

[51]  H. Strobl,et al.  RelB regulates human dendritic cell subset development by promoting monocyte intermediates. , 2004, Blood.

[52]  K. Döhner,et al.  Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. , 2011, Blood.

[53]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[54]  F. Pauler,et al.  An RNA-Seq Strategy to Detect the Complete Coding and Non-Coding Transcriptome Including Full-Length Imprinted Macro ncRNAs , 2011, PloS one.

[55]  A. Esquela-Kerscher,et al.  The complexities of microRNA regulation: mirandering around the rules. , 2010, The international journal of biochemistry & cell biology.

[56]  T. Haferlach,et al.  Monitoring of minimal residual disease in acute myeloid leukemia. , 2005, Critical reviews in oncology/hematology.

[57]  T. Papayannopoulou,et al.  HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. , 1982, Science.

[58]  T. Tuschl,et al.  The Human DiGeorge Syndrome Critical Region Gene 8 and Its D. melanogaster Homolog Are Required for miRNA Biogenesis , 2004, Current Biology.

[59]  C. Croce,et al.  MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. , 2010, Journal of the National Cancer Institute.

[60]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[61]  A. Wölfler,et al.  Therapy‐related myeloid neoplasms: pathobiology and clinical characteristics , 2011, British journal of pharmacology.

[62]  J. T. Syverton,et al.  STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES , 1952, The Journal of experimental medicine.

[63]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[64]  M. Lutherborrow,et al.  The clinicopathological relevance of microRNA in normal and malignant haematopoiesis , 2009, Pathology.